Brief: Crossject secures 6.7 million euros in funding for the development of three new drugs

Crossject SA

06/11/2015 07:30

Nov 6 (Reuters) - Crossject SA  ALCJ.PA : 
    * Crossject secures 6.7 million euros ($7.3 million) in 
funding for the development of three new drugs 
    * Announces that it has been awarded by Bpifrance a 
refundable grant of 6.7 million euros, over three years, as part 
of industrial projects of future (projets industriels d'avenir 
or PIAVE) scheme 
 
Source text for Eikon:  ID:nHUG8F6sdZ  
Further company coverage:  ALCJ.PA  
 
($1 = 0.9198 euros) 
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))